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The immunological composition of the primary cancer,
metastatic sites, and stromal tissue determine cancer pro-
gression and treatment response. Breast cancers produce
cytokines and chemokines that attract and polarize
immune cells in a manner that promotes disease progres-
sion and metastasis. For example, macrophages are polar-
ized to anti-inflammatory type II tumor activating
macrophages (TAMs), and CD4+ T cells into tumor pro-
moting, immune suppressing T regulatory cells (Tregs).
Studies in mice and humans show that Tregs also are
developed when inhibiting the kinase mTOR (mamma-
lian target of rapamycin) via a poorly understood
mechanism. mTOR forms two complexes in the cell,
mTORC1 and mTORC2, which regulate multiple meta-
bolic processes. In particular, mTORC1 is inhibited by
the immunosuppressant rapamycin and stimulates the
translation of mRNAs involved in cell growth and prolif-
eration. Protein synthesis is a highly regulated process
involving general mRNA and selective mRNA translation.
Our hypothesis is that mTOR downregulation alters lym-
phocyte gene expression by favoring the translation of
specific mRNAs required for Treg differentiation.
We generated human Tregs induced in culture (iTregs)
by mTORC1 inhibition through RAD001 (everolimus), a
rapalog used as an anti-cancer drug. By contrast,
mTORC1/2 dual inhibitor PP242 blocked the growth of
all the lymphocytes, pointing to a specific role of
mTORC1 in Treg differentiation. In fact, we found that
the proliferation of highly suppressive iTregs requires co-
treatment with RAD001 and the cytokine TGFb. Murine
models do not require TGFb, suggesting that caution
should be used in extending findings from mouse to
human Treg studies. Protein synthesis analysis in double-
treated (RAD001+TGFb), control-treated, RAD001- and
TGFb-treated cells shows that translation is greatly inhib-
ited in the double-treated cells. Genome-wide translation
profiling of mRNAs associated with actively translating
ribosomes confirmed that only a selective pool of specific
mRNAs is translated in the iTreg population. These speci-
fic mRNAs may be recruited to ribosome via an mTOR-
independent mechanism involving PAIP2, and eIF4G
adapter protein, and the ribosomal protein S25.
Our work indicates the importance of selective transla-
tional regulation as an additional determinant of gene
expression regulating T cell fate. We suggest that iTreg
development is facilitated by selective translation of specific
mRNAs whose recruitment to the ribosome is augmented
when mTORC1 is inhibited. These findings also suggest
that cancer treatments causing an improper balance of
mTORC1 inhibition might attenuate the anti-tumor
immune response through development of Tregs in the
tumor microenvironment
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